1.20
+0.025(+2.14%)
Currency In USD
| Previous Close | 1.17 |
| Open | 1.15 |
| Day High | 1.2 |
| Day Low | 1.14 |
| 52-Week High | 5.92 |
| 52-Week Low | 0.66 |
| Volume | 288,321 |
| Average Volume | 2.26M |
| Market Cap | 136.99M |
| PE | -0.8 |
| EPS | -1.49 |
| Moving Average 50 Days | 1.03 |
| Moving Average 200 Days | 2.1 |
| Change | 0.03 |
If you invested $1000 in Fate Therapeutics, Inc. (FATE) 10 years ago, it would be worth $193.05 as of May 22, 2025 at a share price of $1.195. Whereas If you bought $1000 worth of Fate Therapeutics, Inc. (FATE) shares 5 years ago, it would be worth $33.92 as of May 22, 2025 at a share price of $1.195.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting
GlobeNewswire Inc.
Apr 29, 2025 1:25 PM GMT
Updated clinical and preclinical data showcase iPSC-derived off-the-shelf CAR T-cell therapy products for conditioning chemotherapy-free treatment across autoimmune and cancer indicationsSAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- Fate Therapeuti
Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)
GlobeNewswire Inc.
Apr 14, 2025 12:00 PM GMT
– Recognizes potential of off-the-shelf CAR T-cell therapy to address significant unmet need and enables increased dialogue with FDA throughout the development process – RMAT review by FDA included initial clinical safety and activity data from o
Fate Therapeutics to Present at Upcoming Investor Conferences
GlobeNewswire Inc.
Feb 14, 2025 9:01 PM GMT
SAN DIEGO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies